Month: August 2025

According to unaudited data, VILVI Group‘s consolidated sales revenue for the first half of 2025 amounted to EUR 142.9 million – 22.0% increase compared to the same period of 2024 (consolidated sales revenue in the first six months of 2024 amounted to EUR 117.1 million).The consolidated net profit for the first half of 2025 totaled EUR 8.8 million, whereas in the same period of 2024 it amounted to EUR 10.5 million.The interim unaudited consolidated financial statements for the six months of 2025, together with the presentation of results are enclosed. Vilija MilaseviciuteDirector of Economics and FinancePhone: +370 441 55 102AttachmentThe results of six months 2025

Sampo plc, stock exchange release, 29 August 2025 at 8:30 am EEST Sampo plc’s share buybacks 28 August 2025                                                        On 28 August 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  7,264 9.86 AQEU    115,388 9.86 CEUX  27,728 9.86 TQEX  176,710 9.86 XHELTOTAL 327,090 9.86  * rounded to two decimals                      On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation...

AS LHV Group announces its decision to early redeem the subordinated bonds issued on 30 September 2020, registered under ISIN code EE3300001791 (hereinafter LHV Group 2030 Subordinated Bonds). The early redemption is carried out in accordance with the Prospectus and the Terms and Conditions of the LHV Group 2030 Subordinated Bonds, according to which the bonds may be redeemed early, in whole or in part, after 30 September 2025, provided that the investors are notified at least 30 days in advance and the prior consent of the financial supervision authority has been obtained. On 11 August 2025, the European Central Bank granted its consent for the early redemption of the LHV Group 2030 Subordinated Bonds. All 35,000 of the LHV Group 2030 Subordinated Bonds with a nominal value of EUR 1,000 each and an aggregate nominal value of EUR 35,000,000...

Inside information Ghent, BELGIUM, Aug. 29, 2025 (GLOBE NEWSWIRE) — Biotalys (Euronext – BTLS) today provides an update on the regulatory approval procedure in the United States of its first protein-based biocontrol product, EVOCA™*. Biotalys has received further guidance from the U.S. Environmental Protection Agency (EPA) on the regulatory review of EVOCA. The EPA has confirmed that the scientific review of the dossier is progressing, and that all the requests for additional information have been addressed. While the agency continues to work diligently on the review, the company now expects the final steps of the registration procedure to be taken in Q4, rather than by the end of September as previously anticipated. Kevin Helash, Chief Executive Officer of Biotalys, said: “Biotalys is at the forefront of introducing...

Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. The agreement between Santhera and Ikris has a 5-year term and Santhera will receive a percentage of net sales, in line with previous distribution agreements. Sales are expected to begin in Q4 2025 on a named patient basis. Today’s agreement follows recent distribution deals secured in Turkey and a range of Gulf Cooperation Council countries. Santhera continues to press ahead with the global rollout of AGAMREE. Dario Eklund, Chief Executive Officer of Santhera, said: “We are pleased to partner with Ikris Pharma Network in India,...